Molecular therapy for body weight control, energy homeostasis and TIIDM: Piromelatine,  a melatonin receptor agonist, inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 26/April/2019, 11.19 pm